journal
Journals International Journal of Gynec...

International Journal of Gynecological Cancer

https://read.qxmd.com/read/38876788/utilization-of-artificial-intelligence-to-mitigate-health-inequalities-in-gynecological-cancer-care
#1
JOURNAL ARTICLE
Laila Afroze, Md Sazedur Rahman
No abstract text is available yet for this article.
June 14, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38876787/optimizing-patient-selection-for-secondary-cytoreductive-surgery-in-recurrent-endometrial-cancer
#2
JOURNAL ARTICLE
Virginia Vargiu, Andrea Rosati, Lucia Tortorella, Diana Giannarelli, Vito Andrea Capozzi, Valerio Gallotta, Alessandro Gioè, Ettore Di Stefano, Martina Corrado, Roberto Berretta, Francesco Cosentino, Giovanni Scambia, Francesco Fanfani
OBJECTIVE: This retrospective, multicenter, observational study aimed to refine patient selection criteria for secondary cytoreductive surgery in recurrent endometrial cancer. The objective was to identify preoperative predictors of complete cytoreduction, assess surgical complexity, and propose a preoperative predictive scoring system to identify suitable candidates for secondary cytoreductive surgery. METHODS: Data from 331 women with recurrent endometrial cancer were analyzed across three Italian centers from January 2010 to December 2021...
June 14, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38876786/surgical-site-infection-prevention-bundle-in-gynecology-oncology-surgery-a-key-element-in-the-implementation-of-an-enhanced-recovery-after-surgery-eras-program
#3
REVIEW
Lucia Ribero, María Clara Santía, Kathleen Borchardt, Firaz Zabaneh, Amanda Beck, Archana Sadhu, Karen Edwards, Monica Harrelson, Aimee Pinales-Rodriguez, Elise Mann Yates, Pedro T Ramirez
Surgical site infection rates are among 5-35% in all gynecologic oncology procedures. Such infections lead to increased patient morbidity, reduction in quality of life, higher likelihood of readmissions, and reinterventions, which contribute directly to mortality and increase in health-related costs. Some of these are potentially preventable by applying evidence-based strategies in the peri-operative patient setting. The objective of this review is to provide recommendations for the individual components that most commonly comprise the surgical site infection prevention bundles that could be implemented in gynecologic oncology procedures...
June 14, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38876785/operative-performance-indicators-benchmarking-gynecological-robotic-surgery
#4
JOURNAL ARTICLE
Faiza Gaba, Thomas Edward Ind, Marielle Nobbenhuis
No abstract text is available yet for this article.
June 14, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38862154/investigating-age-and-ethnicity-as-novel-high-risk-phenotypes-in-mucinous-ovarian-cancer-retrospective-study-in-a-multi-ethnic-population
#5
JOURNAL ARTICLE
Tejumola Olaoye, Ayushi -, William Boyle, Anthony Williams, Raji Ganesan, Kamana Subba, Akanksha Goyal, Elaine Leung, Rahul Chowdhary, Jennifer Pascoe, Sarah Williams, Jason Yap, Janos Balega, Satyam Kumar, Kavita Singh, Sudha S Sundar
OBJECTIVES: Primary mucinous ovarian carcinoma represents 3% of ovarian cancers and is typically diagnosed early, yielding favorable outcomes. This study aims to identify risk factors, focussing on the impact of age and ethnicity on survival from primary mucinous ovarian cancer. METHODS: A retrospective observational study of patients treated at Sandwell and West Birmingham Hospitals NHS Trust and University Hospital Coventry and Warwickshire. Patients included were women aged ≥16 years, with primary mucinous ovarian cancer confirmed by specialist gynecological histopathologist and tumor immunohistochemistry, including cytokeratin-7, cytokeratin-20, and CDX2...
June 11, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38858106/a-non-comparative-randomized-phase-ii-trial-of-atezolizumab-or-atezolizumab-plus-tiragolumab-for-programmed-death-ligand-1-positive-recurrent-cervical-cancer-skyscraper-04
#6
JOURNAL ARTICLE
Ritu Salani, Mary McCormack, Yong-Man Kim, Sharad Ghamande, Shaundra L Hall, Domenica Lorusso, Lisa Barraclough, Lucy Gilbert, Adrian Guzman Ramirez, Chien-Hsing Lu, Renaud Sabatier, Nicoletta Colombo, Youyou Hu, Venkatesh Krishnan, Luciana Molinero, Yuning Feng, Nicole Kim, Marcela Castro, Yvonne G Lin, Bradley J Monk
OBJECTIVE: To evaluate tiragolumab (anti-TIGIT) and atezolizumab (anti-PD-L1) as second- or third-line therapy for PD-L1-positive persistent/recurrent cervical cancer. METHODS: In the open-label, non-comparative, randomized phase II SKYSCRAPER-04 trial (NCT04300647), patients with PD-L1-positive (SP263 tumor area positivity ≥5%) recurrent/persistent cervical cancer after 1-2 chemotherapy lines (≥1 platinum-based) were randomized 3:1 to atezolizumab 1200 mg with/without tiragolumab 600 mg every 3 weeks until disease progression or unacceptable toxicity...
June 10, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38858105/effects-of-niraparib-dose-reduction-on-short-term-outcomes-in-ovarian-cancer-patients
#7
JOURNAL ARTICLE
Matteo Bruno, Adriana Ionelia Apostol, Serena Maria Boccia, Carolina Maria Sassu, Sara Lardino, Camilla Culcasi, Domenica Lorusso, Giovanni Scambia, Anna Fagotti, Claudia Marchetti
OBJECTIVES: Despite the individualized starting dose for maintenance therapy in ovarian cancer, the niraparib dose reduction rate remains high. The aim of this study was to evaluate the impact of niraparib dose reduction on progression-free survival in newly diagnosed primary advanced ovarian cancer and recurrent ovarian cancer patients. We also aimed to compare the reduction rates and the safety of niraparib on primary and relapse groups, and identify which factors may predict dose reduction...
June 10, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38858104/notable-surgical-trials-in-gynecologic-oncology-a-10-year-overview
#8
REVIEW
José C Vilches, María Clara Santía, Elise Mann Yates, Rene Pareja, Manuel Lozano, Pedro T Ramirez
In the last decade, we have witnessed important advances in novel therapeutics in the management of gynecologic cancers. These studies have built on the findings from preexisting data and have provided incremental contributions leading to changes that have not only impacted the accuracy of cancer detection and its metastatic components but also led to improvements in oncologic outcomes and quality of life. Key landmark trials have changed the standard of care in cervix, uterine, and ovarian cancer. A number of these have been controversial and have generated significant debate among gynecologic oncologists...
June 10, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38858103/mirvetuximab-soravtansine-in-folate-receptor-alpha-fr%C3%AE-high-platinum-resistant-ovarian-cancer-final-overall-survival-and-post-hoc-sequence-of-therapy-subgroup-results-from-the-soraya-trial
#9
JOURNAL ARTICLE
Robert L Coleman, Domenica Lorusso, Ana Oaknin, Sabrina Chiara Cecere, Hannelore Denys, Nicoletta Colombo, Toon van Gorp, Jason A Konner, Margarita Romeo Marin, Philipp Harter, Conleth Murphy, Yuemei Wang, Brooke Esteves, Michael Method, Ursula Matulonis
OBJECTIVE: The single-arm, phase II SORAYA trial (NCT04296890) of mirvetuximab soravtansine-gynx in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer (n=105 (efficacy-evaluable)) met its primary endpoint with an objective response rate of 32.4% (95% CI, 23.6 to 42.2). Here we report final SORAYA trial results for overall survival and post hoc objective response rates in subgroups by sequence and number of prior therapies. METHODS: Eligible patients had high-grade serous platinum-resistant ovarian cancer with high FRα expression and one to three prior therapies (prior bevacizumab required)...
June 10, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38851241/response-to-correspondence-on-medicolegal-infrastructural-and-financial-aspects-in-gynecologic-cancer-surgery-and-their-implications-in-decision-making-processes-quo-vadis-by-nevin-and-bolton
#10
LETTER
Emma Allanson, Paul A Cohen, Robert Bristow
No abstract text is available yet for this article.
June 8, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38851240/systematic-lymphadenectomy-and-interval-debulking-surgery-less-is-more
#11
EDITORIAL
Francesco Fanfani, Marco D'Indinosante
No abstract text is available yet for this article.
June 8, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38851239/patterns-of-use-of-primary-and-first-line-chemotherapy-for-recurrence-among-patients-with-cervical-cancer
#12
JOURNAL ARTICLE
Alexandra Diggs, Yongmei Huang, Alexander Melamed, Elizabeh Szamreta, Matthew Joseph Monberg, Dawn Hershman, Jason D Wright
BACKGROUND: Little is known about real-world patterns of chemotherapy use in patients with cervical cancer. OBJECTIVE: To examine the patterns of chemotherapy use in patients with cervical cancer METHODS: We identified patients with cervical cancer in the IBM MarketScan Database who underwent primary hysterectomy or radiation therapy between 2011 and 2020 and described their treatment in the primary setting and at first recurrence. RESULTS: We identified 5390 patients: 2667 (49...
June 8, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38851238/correspondence-on-medicolegal-infrastructural-and-financial-aspects-in-gynecologic-cancer-surgery-and-their-implications-in-decision-making-processes-quo-vadis-by-allanson-et-al
#13
LETTER
James Nevin, Helen Bolton
No abstract text is available yet for this article.
June 8, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38839421/impact-of-adjuvant-treatments-and-risk-factors-on-survival-in-2023-figo-stage-iib-endometrial-cancer-patients-turkish-gynecologic-oncology-group-study
#14
JOURNAL ARTICLE
Utku Akgör, Derman Basaran, Mehmet Mutlu Meydanli, Esra Kuscu, Fuat Demirkiran, Samet Topuz, Muzaffer Sancı, Ozgur Akbayır, Murat Gultekin, Mehmet Yavuz Salihoglu, Huseyin Akilli, Tugan Bese, Zeliha Fırat, Hamdullah Sozen, Nejat Ozgul, Ali Ayhan
OBJECTIVE: The aim of this study was to investigate the impact of adjuvant treatments, factors influencing recurrence, and survival data in patients with 2023 International Federation of Gynecology and Obstetrics (FIGO) stage IIB endometrial cancer. METHODS: A retrospective analysis was conducted on patients with endometrial cancer who underwent surgery between 2005 and 2022 at seven different centers in Turkey. Demographic, clinicopathological, and survival data were collected and analyzed...
June 5, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38839080/splenectomy-as-a-part-of-cytoreductive-surgery-in-ovarian-cancer-systematic-review-and-meta-analysis
#15
JOURNAL ARTICLE
Yisi Wang, Yali Chen, Zhaojuan Qin, Mengmeng Chen, Ai Zheng, Ling Han
OBJECTIVE: The role of splenectomy on cytoreductive surgery in patients with ovarian cancer remains controversial. We conducted this meta-analysis to evaluate the safety and impact of survival outcome of splenectomy in patients with ovarian cancer. METHODS: In this meta-analysis we analyzed studies published in PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), International Clinical Trials Registry Platform (ICTRP), and Clinical Trials. gov that appeared in our search from inception to November 10, 2023...
June 4, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38830645/neoadjuvant-chemotherapy-with-bevacizumab-for-locally-advanced-vulvar-cancer
#16
JOURNAL ARTICLE
Theresa M Kuhn, Sarfraz Ahmad, Fernando O Recio, Ahmad Awada, Nathalie D McKenzie, James E Kendrick, Andrew Keller, Robert W Holloway
OBJECTIVES: External beam radiation with sensitizing platinum is the recommended therapy for locally advanced vulvar cancers not amenable to curative surgery and is associated with considerable acute and chronic side effects. Radical vulvectomy post-radiation for persistent disease is often compromised with poor wound healing. We describe clinical outcomes for patients who received neoadjuvant chemotherapy plus bevacizumab followed by radical vulvectomy for locally advanced vulvar cancer...
June 2, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38821546/stereotactic-radiotherapy-for-managing-ovarian-cancer-oligoprogression-under-poly-adp-ribose-polymerase-inhibitors-parpi
#17
JOURNAL ARTICLE
Stefano Durante, Francesco Cuccia, Michele Rigo, Giovanni Caminiti, Federico Mastroleo, Roberta Lazzari, Giulia Corrao, Giuseppe Caruso, Sabrina Vigorito, Federica Cattani, Giuseppe Ferrera, Vito Chiantera, Filippo Alongi, Nicoletta Colombo, Barbara Alicja Jereczek-Fossa
OBJECTIVE: Poly (ADP-ribose) polymerase inhibitors (PARPi) have become a new standard of care for the maintenance treatment of advanced epithelial ovarian cancer. This study aims to evaluate the efficacy and safety of combining stereotactic body radiotherapy with PARPi continuation as a strategy to treat ovarian cancer oligoprogression on PARPi. METHODS: This is a multicenter retrospective study including ovarian cancer patients treated with stereotactic body radiotherapy and PARPi continuation for oligoprogression under PARPi maintenance therapy between June 2012 and May 2023 in three Italian centers...
May 31, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38821545/electronic-malignant-bowel-obstruction-symptom-monitoring-smartphone-application-for-patients-with-gynecologic-cancers
#18
JOURNAL ARTICLE
Ainhoa Madariaga, Nazlin Jivraj, Pamela Soberanis Pina, Faiza Somji, Tran Truong, Sheena Melwani, Mike Lovas, Terri-Ann Gogos, Katrina Sajewycz, Gita Bhat, Husam Alqaisi, Eduardo Gonzalez-Ochoa, Ana Veneziani, Vikas Garg, Neesha C Dhani, Robert Grant, Valerie Bowering, Amit M Oza, Lisa Wang, Alejandro Berlin, Stephanie Lheureux
OBJECTIVES: Implementation of an interprofessional program at Princess Margaret Cancer Centre, including nurse-led proactive calls to support patients with gynecologic cancers with malignant bowel obstruction, demonstrated improved outcomes compared with historical controls. The aim of the study was to convert the proactive calls into an electronic monitoring program to assess it's feasibility and scalability in patients with gynecologic cancers with or at risk of malignant bowel obstruction...
May 31, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38821544/minimally-invasive-surgery-in-the-management-of-early-stage-cervical-cancer-after-the-publication-of-shape-trial
#19
JOURNAL ARTICLE
Sabina Ioana Nistor, Sally El Tawab, Andreas Zouridis, Federico Ferrari, Hooman Soleymani Majd
No abstract text is available yet for this article.
May 31, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38821549/how-deep-is-too-deep-assessing-myometrial-invasion-as-a-predictor-of-distant-recurrence-in-stage-i-endometrioid-endometrial-cancer
#20
JOURNAL ARTICLE
Giorgia Dinoi, Simone Garzon, Amy Weaver, Michaela McGree, Gretchen Glaser, Carrie Langstraat, Amanika Kumar, John Weroha, Allison E Garda, Maryam Shahi, Emilia Palmieri, Giovanni Scambia, Francesco Fanfani, Andrea Mariani
OBJECTIVES: The goal of this study was to evaluate the depth of myometrial invasion as a predictor of distant recurrence in patients with node-negative stage IB endometrioid endometrial cancer. METHODS: A retrospective multicenter study, including surgically staged endometrial cancer patients at Mayo Clinic, Rochester (MN, USA) between January 1999 and December 2017, and Fondazione Policlinico Universitario A. Gemelli (Rome, Italy) between March 2002 and March 2017, was conducted...
May 30, 2024: International Journal of Gynecological Cancer
journal
journal
30825
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.